LXEO

Lexeo Therapeutics, Inc. Common Stock (LXEO) | Rumor.io

Lexeo Therapeutics

LXEO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,822

Bullish sentiment (50-day avg)75%

Price to earnings ratio-1.7

Market capitalization257.8M

Earnings per share-0.88

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-100M

Social

What share of all stock conversation is about LXEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jan 12

LXEO's LX2020 showed positive interim Phase I/II data for treating PKP2-associated arrhythmogenic cardiomyopathy, with increased PKP2 protein expression and stabilized or improved arrhythmia burden.
The treatment was generally well-tolerated across participants, with a mean increase in PKP2 protein of 93% in the low-dose cohort and 162% in the high-dose cohort.
LXEO's shares are trading lower despite the positive data, with some investors viewing it as an overreaction or a good entry point for long positions.

Generated by AI

Sentiment

Of the messages about LXEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	75%	89.91% +3.95
Bearish	—	100% new	25%	10.09% -3.95

Oct 7

Lexeo Therapeutics' stock has surged after the FDA granted accelerated approval progress, with some analysts predicting a price target of $17.00.
The company has a strong cash position, with approximately $133 million in cash, and its lead therapy, LX2006, has received Breakthrough Therapy Designation from the US FDA.
Lexeo Therapeutics has a promising growth outlook, with expected growth of 25-40% and a recent surge in stock price following FDA approval of its key drug, LX2006.

Generated by AI

Topics

Of the messages about LXEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	70%	81.3%
Analysts	—	—	30%	13.01%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.12%
Macro	—	—	0%	5.34%
Technical Analysis	—	—	0%	0.23%

Oct 7

Lexeo Therapeutics, Inc. announced progress in FDA discussions for an accelerated approval pathway for its gene therapy, LX2006, in Friedreich's ataxia cardiomyopathy.
The company reported positive interim clinical data for LX2006, showing sustained cardiac and neurological improvements, including a 23% mean reduction in left ventricular mass and measurable gains in motor function.
Lexeo Therapeutics has approximately $133 million in cash and its lead therapy, LX2006, has received Breakthrough Therapy Designation from the US FDA.

Generated by AI

Community

Of the messages about LXEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	40%	18.84%
Newcomers	100%	90.91%	60%	81.16%

Oct 7

$LXEO's progress in FDA discussions for accelerated approval pathway and positive interim clinical data for LX2006 in Friedreich Ataxia Cardiomyopathy is seen as a major catalyst for the stock.
Newcomers are optimistic about Lexeo Therapeutics, citing a small float, near all-time lows, and the rare disease indication as potential drivers of price movement.
Regulatory alignment is highlighted as a new trend, with $LXEO's price movement being unusually influenced by discussions without new data, suggesting a shift in market dynamics.

Generated by AI

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1) and cross the blood-brain barrier.

7d agoYahoo Finance

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on

7d agoYahoo Finance

Baird reiterates Lexeo Therapeutics stock rating on acquisition deal

7d agoInvesting.com

Why is Lexeo Therapeutics stock gaining today?

7d agoInvesting.com

Also Discussed

Investors talking about LXEO also mention

#	Name	Attention
1	Larimar Therapeutics, Inc.LRMR	0%0
2	Rocket Pharmaceuticals, Inc.RCKT	0%+0
3	PepGen Inc.PEPG	0%new
4	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
5	Abivax SAABVX	0.01%-0.01
6	Regenxbio Inc.RGNX	0%+0
7	Wave Life Sciences Ltd.WVE	0%+0
8	uniQure N.V.QURE	0.02%+0.01
9	SLNO - Soleno Therapeutics, Inc.	——
10	VTYX - Ventyx Biosciences, Inc.	——

Lexeo Therapeutics, Inc. Common Stock

Healthcare
Biotechnology

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.

Website

Location

345 Park Avenue South

New York, NY, 10010

United States

Social

What share of all stock conversation is about LXEO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% +0

Jan 12

LXEO's LX2020 showed positive interim Phase I/II data for treating PKP2-associated arrhythmogenic cardiomyopathy, with increased PKP2 protein expression and stabilized or improved arrhythmia burden.
The treatment was generally well-tolerated across participants, with a mean increase in PKP2 protein of 93% in the low-dose cohort and 162% in the high-dose cohort.
LXEO's shares are trading lower despite the positive data, with some investors viewing it as an overreaction or a good entry point for long positions.

Generated by AI

Sentiment

Of the messages about LXEO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	75%	89.91% +3.95
Bearish	—	100% new	25%	10.09% -3.95

Oct 7

Lexeo Therapeutics' stock has surged after the FDA granted accelerated approval progress, with some analysts predicting a price target of $17.00.
The company has a strong cash position, with approximately $133 million in cash, and its lead therapy, LX2006, has received Breakthrough Therapy Designation from the US FDA.
Lexeo Therapeutics has a promising growth outlook, with expected growth of 25-40% and a recent surge in stock price following FDA approval of its key drug, LX2006.

Generated by AI

Topics

Of the messages about LXEO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	70%	81.3%
Analysts	—	—	30%	13.01%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.12%
Macro	—	—	0%	5.34%
Technical Analysis	—	—	0%	0.23%

Oct 7

Lexeo Therapeutics, Inc. announced progress in FDA discussions for an accelerated approval pathway for its gene therapy, LX2006, in Friedreich's ataxia cardiomyopathy.
The company reported positive interim clinical data for LX2006, showing sustained cardiac and neurological improvements, including a 23% mean reduction in left ventricular mass and measurable gains in motor function.
Lexeo Therapeutics has approximately $133 million in cash and its lead therapy, LX2006, has received Breakthrough Therapy Designation from the US FDA.

Generated by AI

Community

Of the messages about LXEO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	40%	18.84%
Newcomers	100%	90.91%	60%	81.16%

Oct 7

$LXEO's progress in FDA discussions for accelerated approval pathway and positive interim clinical data for LX2006 in Friedreich Ataxia Cardiomyopathy is seen as a major catalyst for the stock.
Newcomers are optimistic about Lexeo Therapeutics, citing a small float, near all-time lows, and the rare disease indication as potential drivers of price movement.
Regulatory alignment is highlighted as a new trend, with $LXEO's price movement being unusually influenced by discussions without new data, suggesting a shift in market dynamics.

Generated by AI

Lexeo Therapeutics

Social

Jan 12

Sentiment

Oct 7

Topics

Oct 7

Community

Oct 7

News

Lexeo Therapeutics completes acquisition of Mantle Therapeutics

Lexeo gains access to Apertura’s gene therapy capsid

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Baird reiterates Lexeo Therapeutics stock rating on acquisition deal

Why is Lexeo Therapeutics stock gaining today?

Also Discussed

Lexeo Therapeutics, Inc. Common Stock

Company Information

Location

News

Lexeo Therapeutics completes acquisition of Mantle Therapeutics

Lexeo gains access to Apertura’s gene therapy capsid

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Baird reiterates Lexeo Therapeutics stock rating on acquisition deal

Why is Lexeo Therapeutics stock gaining today?

Also Discussed

Social

Jan 12

Sentiment

Oct 7

Topics

Oct 7

Community

Oct 7